Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease

Journal of Neurochemistry

Volumn 141, Issue 5, 2017, Pages 766-782

  Ay, Muhammet ^a   Luo, Jie ^a   Langley, Monica ^a   Jin, Huajun ^a   Anantharam, Vellareddy ^a   Kanthasamy, Arthi ^a   Kanthasamy, Anumantha G ^a  

^a IOWA STATE UNIVERSITY   (United States)

Author keywords

mitochondrial biogenesis; MitoPark; Parkinson's disease; PGC 1 ; PKD1; quercetin

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; OXIDOPAMINE; POLYCYSTIN 1; PROTEIN KINASE B; QUERCETIN; SMALL INTERFERING RNA; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIOXIDANT; DNA BINDING PROTEIN; DOPAMINE; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL TRANSCRIPTION FACTOR A; POLYCYSTIC KIDNEY DISEASE 1 PROTEIN; POLYCYSTIN; TRANSCRIPTION FACTOR; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CELL CULTURE; CELL LINE; CELL LOSS; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DETERMINATION; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE TARGETING; MALE; MITOCHONDRIAL BIOGENESIS; MITOTRACKER ASSAY; MN9D CELL LINE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; COMPLICATION; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENETICS; METABOLISM; MITOCHONDRIAL DISEASES; OXYGEN CONSUMPTION; PHOSPHORYLATION; TRANSFORMED CELL LINE; TRANSGENIC MOUSE;

ADRENERGIC AGENTS; ANIMALS; ANTIOXIDANTS; CELL LINE, TRANSFORMED; CELL SURVIVAL; DNA-BINDING PROTEINS; DOPAMINE; EXPLORATORY BEHAVIOR; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIAL DISEASES; MITOCHONDRIAL PROTEINS; NERVE DEGENERATION; OXIDOPAMINE; OXYGEN CONSUMPTION; PARKINSON DISEASE; PHOSPHORYLATION; QUERCETIN; TRANSCRIPTION FACTORS; TRPP CATION CHANNELS; TYROSINE 3-MONOOXYGENASE;

EID: 85019132092     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.14033     Document Type: Article

References (98)

1. Ahn T. B. and Jeon B. S. (2015) The role of quercetin on the survival of neuron-like PC12 cells and the expression of alpha-synuclein. Neural Regen. Res. 10, 1113–1119.
2. Akimoto T., Li P. and Yan Z. (2008) Functional interaction of regulatory factors with the Pgc-1alpha promoter in response to exercise by in vivo imaging. Am. J. Physiol. Cell Physiol. 295, C288–C292.
3. Anantharam V., Kitazawa M., Wagner J., Kaul S. and Kanthasamy A. G. (2002) Caspase-3-dependent proteolytic cleavage of protein kinase Cdelta is essential for oxidative stress-mediated dopaminergic cell death after exposure to methylcyclopentadienyl manganese tricarbonyl. J. Neurosci. 22, 1738–1751.
4. Anderson D. W., Bradbury K. A. and Schneider J. S. (2006) Neuroprotection in Parkinson models varies with toxin administration protocol. Eur. J. Neuorsci. 24, 3174–3182.
5. Ansari M. A., Abdul H. M., Joshi G., Opii W. O. and Butterfield D. A. (2009) Protective effect of quercetin in primary neurons against Abeta(1-42): relevance to Alzheimer's disease. J. Nutr. Biochem. 20, 269–275.
6. Asaithambi A., Kanthasamy A., Saminathan H., Anantharam V. and Kanthasamy A. G. (2011) Protein kinase D1 (PKD1) activation mediates a compensatory protective response during early stages of oxidative stress-induced neuronal degeneration. Mol. Neurodegener. 6, 43.
7. Asaithambi A., Ay M., Jin H., Gosh A., Anantharam V., Kanthasamy A. and Kanthasamy A. G. (2014) Protein kinase D1 (PKD1) phosphorylation promotes dopaminergic neuronal survival during 6-OHDA-induced oxidative stress. PLoS ONE 9, e96947.
8. Ay M., Jin H., Harischandra D. S., Asaithambi A., Kanthasamy A., Anantharam V. and Kanthasamy A. G. (2015) Molecular cloning, epigenetic regulation, and functional characterization of Prkd1 gene promoter in dopaminergic cell culture models of Parkinson's disease. J. Neurochem. 135, 402–415.
9. Barneda-Zahonero B., Servitja J. M., Badiola N., Minano-Molina A. J., Fado R., Saura C. A. and Rodriguez-Alvarez J. (2012) Nurr1 protein is required for N-methyl-D-aspartic acid (NMDA) receptor-mediated neuronal survival. J. Biol. Chem. 287, 11351–11362.
10. Barrenetxe J., Aranguren P., Grijalba A., Martinez-Penuela J. M., Marzo F. and Urdaneta E. (2006) Effect of dietary quercetin and sphingomyelin on intestinal nutrient absorption and animal growth. Br. J. Nutr. 95, 455–461.
11. Boots A. W., Wilms L. C., Swennen E. L., Kleinjans J. C., Bast A. and Haenen G. R. (2008) In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition 24, 703–710.
12. Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254.
13. Branch S. Y., Chen C., Sharma R., Lechleiter J. D., Li S. and Beckstead M. J. (2016) Dopaminergic neurons exhibit an age-dependent decline in electrophysiological parameters in the MitoPark mouse model of Parkinson's disease. J. Neurosci. 36, 4026–4037.
14. Cardoso S. M., Moreira P. I., Agostinho P., Pereira C. and Oliveira C. R. (2005) Neurodegenerative pathways in Parkinson's disease: therapeutic strategies. Curr. Drug Targets 4, 405–419.
15. Casuso R. A., Martinez-Amat A., Martinez-Lopez E. J., Camiletti-Moiron D., Porres J. M. and Aranda P. (2013) Ergogenic effects of quercetin supplementation in trained rats. J. Int. Soc. Sports Nutr. 10, 3.
16. Chakraborty J., Singh R., Dutta D., Naskar A., Rajamma U. and Mohanakumar K. P. (2014) Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington's Disease. CNS Neurosci. Ther. 20, 10–19.
17. Charli A., Jin H., Anantharam V., Kanthasamy A. and Kanthasamy A. G. (2016) Alterations in mitochondrial dynamics induced by tebufenpyrad and pyridaben in a dopaminergic neuronal cell culture model. Neurotoxicology 53, 302–313.
18. Chaudhuri K. R. and Schapira A. H. (2009) Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 8, 464–474.
19. Chen J., Deng F., Singh S. V. and Wang Q. J. (2008) Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2. Can. Res. 68, 3844–3853.
20. Chen B., Ma X. L., Geng Z., Huang S. H., Zhai L. K., Guo Y. Y. and Chen Z. Y. (2015) Up-regulation of c-Jun NH2-terminal kinase-interacting protein 3 (JIP3) contributes to BDNF-enhanced neurotransmitter release. J. Neurochem. 135, 453–465.
21. Choi E. J. and Kim G. H. (2010) Quercetin accumulation by chronic administration causes the caspase-3 activation in liver and brain of mice. BioFactors 36, 216–221.
22. Clark J. and Simon D. K. (2009) Transcribe to survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. Antioxid. Redox Signal. 11, 509–528.
23. Cui L., Jeong H., Borovecki F., Parkhurst C. N., Tanese N. and Krainc D. (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127, 59–69.
24. Dauer W. and Przedborski S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889–909.
25. Devi L. and Ohno M. (2015) TrkB reduction exacerbates Alzheimer's disease-like signaling aberrations and memory deficits without affecting beta-amyloidosis in 5XFAD mice. Transl. Psychiat. 5, e562.
26. Dranka B. P., Hill B. G. and Darley-Usmar V. M. (2010) Mitochondrial reserve capacity in endothelial cells: The impact of nitric oxide and reactive oxygen species. Free Radic. Biol. Med. 48, 905–914.
27. Dranka B. P., Benavides G. A., Diers A. R. et al. (2011) Assessing bioenergetic function in response to oxidative stress by metabolic profiling. Free Radic. Biol. Med. 51, 1621–1635.
28. Durgadoss L., Nidadavolu P., Valli R. K., Saeed U., Mishra M., Seth P. and Ravindranath V. (2012) Redox modification of Akt mediated by the dopaminergic neurotoxin MPTP, in mouse midbrain, leads to down-regulation of pAkt. FASEB J. 26, 1473–1483.
29. Duthie S. J. and Dobson V. L. (1999) Dietary flavonoids protect human colonocyte DNA from oxidative attack in vitro. Eur. J. Nutr. 38, 28–34.
30. Egert S., Bosy-Westphal A., Seiberl J. et al. (2009) Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br. J. Nutr. 102, 1065–1074.
31. Ekstrand M. I., Terzioglu M., Galter D. et al. (2007) Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl Acad. Sci. USA 104, 1325–1330.
32. Etminan M., Gill S. S. and Samii A. (2005) Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurol. 4, 362–365.
33. Fahn S. (1992) A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann. Neurol. 32(Suppl), S128–S132.
34. Galter D., Pernold K., Yoshitake T., Lindqvist E., Hoffer B., Kehr J., Larsson N. G. and Olson L. (2010) MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease. Genes Brain Behav. 9, 173–181.
35. Ghosh A., Chandran K., Kalivendi S. V., Joseph J., Antholine W. E., Hillard C. J., Kanthasamy A., Kanthasamy A. and Kalyanaraman B. (2010) Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. Free Radic. Biol. Med. 49, 1674–1684.
36. Ghosh A., Saminathan H., Kanthasamy A. et al. (2013) The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of Parkinson disease. J. Biol. Chem. 288, 21955–21971.
37. Ghosh A., Langley M. R., Harischandra D. S. et al. (2016) Mitoapocynin treatment protects against neuroinflammation and dopaminergic neurodegeneration in a preclinical animal model of Parkinson's disease. J. Neuroimmune Pharmacol. 11, 259–278.
38. Good C. H., Hoffman A. F., Hoffer B. J. et al. (2011) Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease. FASEB J. 25, 1333–1344.
39. Gordon R., Neal M. L., Luo J. et al. (2016) Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration. Nat. Commun. 7, 12932.
40. Gubellini P. and Kachidian P. (2015) Animal models of Parkinson's disease: an updated overview. Rev. Neurol. (Paris) 171, 750–761.
41. Haleagrahara N., Siew C. J., Mitra N. K. and Kumari M. (2011) Neuroprotective effect of bioflavonoid quercetin in 6-hydroxydopamine-induced oxidative stress biomarkers in the rat striatum. Neurosci. Lett. 500, 139–143.
42. Harwood M., Danielewska-Nikiel B., Borzelleca J. F., Flamm G. W., Williams G. M. and Lines T. C. (2007) A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem. Toxicol. 45, 2179–2205.
43. Hertog M. G., Kromhout D., Aravanis C. et al. (1995) Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch. Intern. Med. 155, 381–386.
44. Herzig S., Long F., Jhala U. S. et al. (2001) CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413, 179–183.
45. Humbert S., Bryson E. A., Cordelieres F. P., Connors N. C., Datta S. R., Finkbeiner S., Greenberg M. E. and Saudou F. (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2, 831–837.
46. Ishisaka A., Ichikawa S., Sakakibara H. et al. (2011) Accumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats. Free Radic. Biol. Med. 51, 1329–1336.
47. Jakubowicz-Gil J., Rzeski W., Zdzisinska B., Piersiak T., Weiksza K., Glowniak K. and Gawron A. (2008) Different sensitivity of neurons and neuroblastoma cells to quercetin treatment. Acta Neurobiol. Exp. 68, 463–476.
48. Jin F., Nieman D. C., Shanely R. A., Knab A. M., Austin M. D. and Sha W. (2010) The variable plasma quercetin response to 12-week quercetin supplementation in humans. Eur. J. Clin. Nutr. 64, 692–697.
49. Jin H., Kanthasamy A., Anantharam V., Rana A. and Kanthasamy A. G. (2011) Transcriptional regulation of pro-apoptotic protein kinase Cdelta: implications for oxidative stress-induced neuronal cell death. J. Biol. Chem. 286, 19840–19859.
50. Jin H., Kanthasamy A., Harischandra D. S., Kondru N., Ghosh A., Panicker N., Anantharam V., Rana A. and Kanthasamy A. G. (2014) Histone hyperacetylation up-regulates protein kinase cdelta in dopaminergic neurons to induce cell death: relevance to epigenetic mechanisms of neurodegeneration in Parkinson disease. J. Biol. Chem. 289, 34743–34767.
51. Johannessen M., Delghandi M. P. and Moens U. (2004) What turns CREB on? Cell. Signal. 16, 1211–1227.
52. Johannessen M., Delghandi M. P., Rykx A., Dragset M., Vandenheede J. R., Van Lint J. and Moens U. (2007) Protein kinase D induces transcription through direct phosphorylation of the cAMP-response element-binding protein. J. Biol. Chem. 282, 14777–14787.
53. Jourdi H., Hamo L., Oka T., Seegan A. and Baudry M. (2009) BDNF mediates the neuroprotective effects of positive AMPA receptor modulators against MPP+-induced toxicity in cultured hippocampal and mesencephalic slices. Neuropharmacology 56, 876–885.
54. Kalia L. V. and Lang A. E. (2015) Parkinson's disease. Lancet 386, 896–912.
55. Karuppagounder S. S., Madathil S. K., Pandey M., Haobam R., Rajamma U. and Mohanakumar K. P. (2013) Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats. Neuroscience 236, 136–148.
56. Knab A. M., Shanely R. A., Jin F., Austin M. D., Sha W. and Nieman D. C. (2011) Quercetin with vitamin C and niacin does not affect body mass or composition. Appl. Physiol. Nutr. Metab. 36, 331–338.
57. Kwon S. M., Park H. G., Jun J. K. and Lee W. L. (2014) Exercise, but not quercetin, ameliorates inflammation, mitochondrial biogenesis, and lipid metabolism in skeletal muscle after strenuous exercise by high-fat diet mice. J. Exerc. Nutrition Biochem. 18, 51–60.
58. Langley M., Ghosh A., Charli A., Sarkar S., Ay M., Luo J., Zielonka J., Brenza T., Bennett B., Jin H., Ghaisas S., Schlichtmann B., Kim D., Anantharam V., Kanthasamy A., Narasimhan B., Kalyanaraman B. and Kanthasamy A. G. (2017) Mito-apocynin prevents mitochondrial dysfunction, microglial activation, oxidative damage, and progressive neurodegeneration in MitoPark transgenic mice. Antioxidants & Redox Signaling. April 2017. doi:10.1089/ars.2016.6905. [ahead of print]
59. Lees A. J., Hardy J. and Revesz T. (2009) Parkinson's disease. Lancet 373, 2055–2066.
60. Lehmann S., Costa A. C., Celardo I., Loh S. H. and Martins L. M. (2016) Parp mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson's disease. Cell Death Dis. 7, e2166.
61. Li L., Pan R., Li R., Niemann B., Aurich A. C., Chen Y. and Rohrbach S. (2011) Mitochondrial biogenesis and peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) deacetylation by physical activity: intact adipocytokine signaling is required. Diabetes 60, 157–167.
62. Liu Z., Liu Y., Gao R., Li H., Dunn T., Wu P., Smith R. G., Sarkar P. S. and Fang X. (2014) Ethanol suppresses PGC-1alpha expression by interfering with the cAMP-CREB pathway in neuronal cells. PLoS ONE 9, e104247.
63. Lonze B. E. and Ginty D. D. (2002) Function and regulation of CREB family transcription factors in the nervous system. Neuron 35, 605–623.
64. Lv C., Hong T., Yang Z., Zhang Y., Wang L., Dong M., Zhao J., Mu J. and Meng Y. (2012) Effect of quercetin in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced mouse model of Parkinson's disease. Evid. Based Complement. Alternat. Med. 2012, 928643.
65. Marcellino D., Lindqvist E., Schneider M., Müller C. E., Fuxe K., Olson L. and Galter D. (2010) Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice. Neurobiol Dis. 40, 460–466.
66. Marjama-Lyons J. and Koller W. (2000) Tremor-predominant Parkinson's disease. Approaches to treatment. Drugs Aging 16, 273–278.
67. Meller R., Minami M., Cameron J. A., Impey S., Chen D., Lan J. Q., Henshall D. C. and Simon R. P. (2005) CREB-mediated Bcl-2 protein expression after ischemic preconditioning. J. Cereb. Blood Flow Metab. 25, 234–246.
68. Ngo H. B., Kaiser J. T. and Chan D. C. (2011) The mitochondrial transcription and packaging factor Tfam imposes a U-turn on mitochondrial DNA. Nat. Struct. Mol. Biol. 18, 1290–1296.
69. Olanow C. W. and Tatton W. G. (1999) Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22, 123–144.
70. Onyango I. G. (2008) Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Neurochem. Res. 33, 589–597.
71. Quindry J. C., McAnulty S. R., Hudson M. B., Hosick P., Dumke C., McAnulty L. S., Henson D., Morrow J. D. and Nieman D. (2008) Oral quercetin supplementation and blood oxidative capacity in response to ultramarathon competition. Int J Sport Nutr Exerc. Metab. 18, 601–616.
72. Ramos F. A., Takaishi Y., Shirotori M., Kawaguchi Y., Tsuchiya K., Shibata H., Higuti T., Tadokoro T. and Takeuchi M. (2006) Antibacterial and antioxidant activities of quercetin oxidation products from yellow onion (Allium cepa) skin. J. Agric. Food Chem. 54, 3551–3557.
73. Ries V., Henchcliffe C., Kareva T., Rzhetskaya M., Bland R., During M. J., Kholodilov N. and Burke R. E. (2006) Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc. Natl Acad. Sci. USA 103, 18757–18762.
74. Ruiz M. J., Fernandez M., Pico Y., Manes J., Asensi M., Carda C., Asensio G. and Estrela J. M. (2009) Dietary administration of high doses of pterostilbene and quercetin to mice is not toxic. J. Agric. Food Chem. 57, 3180–3186.
75. Sabogal-Guaqueta A. M., Munoz-Manco J. I., Ramirez-Pineda J. R., Lamprea-Rodriguez M., Osorio E. and Cardona-Gomez G. P. (2015) The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice. Neuropharmacology 93C, 134–145.
76. Saleem A., Carter H. N. and Hood D. A. (2014) p53 is necessary for the adaptive changes in cellular milieu subsequent to an acute bout of endurance exercise. Am. J. Physiol. Cell Physiol. 306, C241–C249.
77. Scarpulla R. C. (2008) Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol. Rev. 88, 611–638.
78. Schapira A. H. (2008) Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 7, 97–109.
79. Scheider W. L., Hershey L. A., Vena J. E., Holmlund T. and Marshall J. R. and Freudenheim (1997) Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease. Mov. Disord., 12, 190–196.
80. Seidl S. E. and Potashkin J. A. (2011) The promise of neuroprotective agents in Parkinson's disease. Front. Neurol. 2, 68.
81. Sharlow E. R., Giridhar K. V., LaValle C. R. et al. (2008) Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. J. Biol. Chem. 283, 33516–33526.
82. Shieh P. B., Hu S. C., Bobb K., Timmusk T. and Ghosh A. (1998) Identification of a signaling pathway involved in calcium regulation of BDNF expression. Neuron 20, 727–740.
83. Shin J. H., Ko H. S., Kang H., Lee Y., Lee Y. I., Pletinkova O., Troconso J. C., Dawson V. L. and Dawson T. M. (2011) PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 144, 689–702.
84. Siddiqui A., Chinta S. J., Mallajosyula J. K., Rajagopolan S., Hanson I., Rane A., Melov S. and Andersen J. K. (2012) Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease. Free Radic. Biol. Med. 53, 993–1003.
85. Smith K. M., Browne S. E., Jayaraman S., Bleickardt C. J., Hodge L. M., Lis E., Yao L., Rittle S. L., Innocent N., Mullins D. E., Boykow G., Reynolds I. J., Hill D., Parker E. M. and Hodgson R. A. (2014) Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice. Eur J Pharmacol. 728, 31–38.
86. Struewing I. T., Barnett C. D., Tang T. and Mao C. D. (2007) Lithium increases PGC-1alpha expression and mitochondrial biogenesis in primary bovine aortic endothelial cells. FEBS J. 274, 2749–2765.
87. Tao X., Finkbeiner S., Arnold D. B., Shaywitz A. J. and Greenberg M. E. (1998) Ca2 + influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20, 709–726.
88. Torres-Marquez E., Sinnett-Smith J., Guha S., Kui R., Waldron R. T., Rey O. and Rozengurt E. (2010) CID755673 enhances mitogenic signaling by phorbol esters, bombesin and EGF through a protein kinase D-independent pathway. Biochem. Biophys. Res. Commun. 391, 63–68.
89. Tritos N. A., Mastaitis J. W., Kokkotou E. G., Puigserver P., Spiegelman B. M. and Maratos-Flier E. (2003) Characterization of the peroxisome proliferator activated receptor coactivator 1 alpha (PGC 1alpha) expression in the murine brain. Brain Res. 961, 255–260.
90. Tufi R., Gandhi S., de Castro I. P. et al. (2014) Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease. Nat. Cell Biol. 16, 157–166.
91. Wu Z., Puigserver P., Andersson U. et al. (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98, 115–124.
92. Xu J., Xu S. Q., Liang J., Lu Y., Luo J. H. and Jin J. H. (2012) [Protective effect of nicotinamide in a mouse Parkinson's disease model]. Zhejiang Da Xue Xue Bao Yi Xue Ban 41, 146–152.
93. Yang D., Peng C., Li X., Fan X., Li L., Ming M., Chen S. and Le W. (2008) Pitx3-transfected astrocytes secrete brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor and protect dopamine neurons in mesencephalon cultures. J. Neurosci. Res. 86, 3393–3400.
94. Youdim M. B. and Oh Y. J. (2013) Promise of neurorestoration and mitochondrial biogenesis in Parkinson's disease with multi target drugs: an alternative to stem cell therapy. Exp. Neurobiol. 22, 167–172.
95. Zandi K., Teoh B. T., Sam S. S., Wong P. F., Mustafa M. R. and Abubakar S. (2011) Antiviral activity of four types of bioflavonoid against dengue virus type-2. Virol. J. 8, 560.
96. Zhang S. M., Hernan M. A., Chen H., Spiegelman D., Willett W. C. and Ascherio A. (2002) Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59, 1161–1169.
97. Zhang L., Qu Y., Tang J., Chen D., Fu X., Mao M. and Mu D. (2010) PI3K/Akt signaling pathway is required for neuroprotection of thalidomide on hypoxic-ischemic cortical neurons in vitro. Brain Res. 1357, 157–165.
98. Zheng B., Liao Z., Locascio J. J. et al. (2010) PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med. 2, 52ra73.